GentiBio
Cell & Gene Therapy · Health Care
Sponsors visas
Lately:1 news story in 90 daysFollow changes →
Facts
as of Nov 17, 2026Our modular engineering platform allows us to create optimized Tregs phenotypes tailored to address a wide variety of autoimmune, alloimmune and inflammatory diseases.
- Headquarters
- Cambridge, United States
- Official records
- Wikidata Q140876913
- Website
- gentibio.com
These are the key facts about GentiBio on Alion as of Nov 17, 2026. GentiBio is headquartered in Cambridge, United States. The latest round is Series A of $157M, announced in 2021.
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake
What the registers and the postings say about this employer.
Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices
Visa
Full chapter →Named in the work visa registers of United States.
United StatesUS 1
#5,756 of 8,997 sponsors
1H-1B filings in 12 months
$168kMedian offered salary
0Open roles in United States
Who they sponsor
The salary offered for each occupationVisa pass · 90 credits In the register as GentiBio, Inc., Cambridge, MA
Other sponsors in the same field
Aldevron 11 filingsVyriad 5 filingsCoriell Institute for Medical Research 1 filingsOverT Bio 1 filings
Alert me
US Department of Labor · latest filing Feb 24, 2026
Footprint
Hiring in 1 city in 1 country.
1Cities
1Countries
| Site | Type | Open roles | Hires most for | Engineering |
|---|---|---|---|---|
| Cambridge United States | Headquarters | 0 |
Source: office addresses in postings and company registers
Financials
Funding rounds, investors and revenue on record.
$157MTotal raised
$1.2MPublic grants1 public grant
GrantLatest round
2Rounds and grants
Sources: funding announcements, grant and company registers
Milestones
Aug 15, 2025
Won a grant $1.2M · CORDIS
Aug 10, 2022
Aug 10, 2021
Raised a round Series A $157M
Sep 2020
Website went live first capture in the Wayback Machine
Each milestone is dated by its source: registers, filings, the press
Newsroom
Sep 252026
News · pharmaphorum
Bristol-Myers Squibb has formed an R&D partnership with GentiBio, aimed at developing regulatory T cel (Treg) therapies for inflammatory bowel disease (IBD). The deal includes an…
Mar 182026
Press release · PRNewswire
/PRNewswire/ -- GentiBio, Inc., a clinical-stage biotechnology company pioneering engineered, antigen-specific regulatory T cell (EngTreg) therapies, today...
Mar 22, 20242024
Mar 7, 20242024
Aug 10, 20222022
News · bizjournals.com
Aug 11, 20212021
Sources: the outlets named on each headline, each story once
